Enhabit, Inc. (NYSE:EHAB) Receives Consensus Rating of “Reduce” from Brokerages

Enhabit, Inc. (NYSE:EHAB) has received a consensus recommendation of “Reduce” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $9.79.

Several analysts recently weighed in on the company. Oppenheimer restated a “market perform” rating on shares of Enhabit in a research report on Thursday, March 7th. Leerink Partnrs upgraded shares of Enhabit from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 14th. Jefferies Financial Group cut shares of Enhabit from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $14.00 to $8.75 in a research report on Thursday, May 9th. Bank of America cut their target price on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating on the stock in a research report on Thursday, June 27th. Finally, UBS Group upgraded shares of Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 price target for the company in a report on Thursday, March 7th.

Insiders Place Their Bets

In other news, Director Jeffrey Bolton bought 10,000 shares of Enhabit stock in a transaction dated Friday, May 10th. The stock was bought at an average cost of $8.24 per share, for a total transaction of $82,400.00. Following the purchase, the director now directly owns 42,299 shares in the company, valued at approximately $348,543.76. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders acquired 22,000 shares of company stock worth $183,700. 1.90% of the stock is owned by corporate insiders.

Institutional Trading of Enhabit

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gladius Capital Management LP bought a new stake in Enhabit during the fourth quarter worth $42,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Enhabit in the 1st quarter worth $44,000. ProShare Advisors LLC purchased a new stake in shares of Enhabit in the first quarter valued at about $118,000. Family Firm Inc. bought a new position in shares of Enhabit during the first quarter valued at about $124,000. Finally, Covestor Ltd boosted its holdings in Enhabit by 1,130.0% during the first quarter. Covestor Ltd now owns 13,456 shares of the company’s stock worth $157,000 after purchasing an additional 12,362 shares during the last quarter.

Enhabit Price Performance

EHAB stock opened at $8.78 on Tuesday. The company’s 50-day moving average price is $9.16 and its two-hundred day moving average price is $9.85. The firm has a market cap of $440.40 million, a P/E ratio of -5.29, a P/E/G ratio of 1.43 and a beta of 1.86. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.75. Enhabit has a 12 month low of $7.12 and a 12 month high of $14.59.

Enhabit (NYSE:EHAB) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. The business had revenue of $262.40 million for the quarter, compared to analysts’ expectations of $268.25 million. On average, analysts anticipate that Enhabit will post 0.24 earnings per share for the current fiscal year.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.